Comparison of three moderate fractionated schedules employed in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer.

CONCLUSIONS: The 3 schedules showed equivocal outcomes in each risk group, with different toxicity profiles. HDR-BT monotherapy with these schedules is an acceptable treatment option for localized prostate cancer. PMID: 30190166 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30190166?dopt=Abstract

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - September 3, 2018 Category: Radiology Authors: Yamazaki H, Masui K, Suzuki G, Nakamura S, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K Tags: Radiother Oncol Source Type: research